Additional file 2: Table S2. of Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer

Number of ES-SCLC Patients with Thoracic Progression after Initial Chemotherapy Based on the Primary Tumor Size or the Number of Metastatic Sites. (DOC 92 kb

Additional file 4: Figure S2. of Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer

Association between Progression Free Survival and Overall Survival for ES-SCLC Patients in This Study. Blue circles represent individual patients with ES-SCLC. (DOC 92 kb

Additional file 1: Table S1. of Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer

Assessment of the Well-Known and Potential Prognostic Factors for Overall Survival in ES-SCLC Patients. (DOC 61 kb

Representative cases of each EMT phenotype according to expression of E-cadherin and vimentin.

<p>The cases are divided into the following 4 phenotypes; complete type, incomplete type1 (hybrid type), incomplete type2 (null type), and wild type (Lo, loss; Pr, preserve; P, positive; N, negative. original magnification, ×200).</p

Relationships between nestin expression and clinicopathological parameters.

<p>Relationships between nestin expression and clinicopathological parameters.</p

Cumulative survival of patients with NSCLC according to nestin expression estimated by the Kaplan-Meier method.

<p>Panel (A) and (B) shows disease-free survival (DFS) and overall survival (OS), respectively. Nestin expression is significantly associated with poorer survival in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy, whereas there was no association between DFS and nestin expression.</p

Representative images of immunohistochemical staining of NSCLC samples.

<p>(A) Nestin, (B) ABCG2, (C) E-cadherin, and (D) Vimentin show positive expression. (original magnification, ×200).</p